TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8919896
Drug: Contrast injection
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast injection during ventilation with PEEP (15 cm H2O), a tidal volume of 1,200 ml, and a respiratory rate of 6/min (Manoeuvre II)
Study: 1907075
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (105 grams total in 1050 millilitres solution)
Study: 21425573
Drug: Integrated medical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated medical protocol (Chinese medical therapy plus conventional Western medical treatment)
Study: 21425573
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical treatment plus placebo
Study: 20353621
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT)
Study: 824298
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg TRH taken twice daily for four weeks
Study: 824298
Drug: 5-20 mg
Normalized name: Clinimix 5/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-20 mg TRH taken twice daily for five days
Study: 26279104
Drug: Transcutaneous PTNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous PTNS (voltage pulse intensity of 0 to 10 mA, pulse width of 200 μs, frequency of 20 Hz, 30 min weekly for 12 weeks)
Study: 26279104
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (no stimulation, patch electrodes applied)
Study: 16432272
Drug: Milk thistle
Normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk thistle (900 mg) for 14 days
Study: 16432272
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh (80 mg) for 14 days
Study: 16432272
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg) for 7 days
Study: 16432272
Drug: Clarithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (1000 mg) for 7 days
Study: 1288512
Drug: Bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (600 mg)
Study: 30862293
Drug: Integrated depression-alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated depression-alcohol misuse cognitive-behaviour therapy (CBT)
Study: 27756485
Drug: Vaccine (Merck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (Merck Adenovirus‐5 Gag/Pol/Nef HIV‐1 subtype‐B vaccine)
Study: 22307266
Drug: Delayed zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed zoledronic acid (4 mg intravenously every 6 months)
Study: 10470769
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in ordering practice: No standing orders for routine daily morning chest radiographs; each radiograph requires a written order and clinical indication.
Study: 2195152
Drug: Toothpaste and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste and oral rinse containing sanguinaria extract and zinc chloride
Study: 29559771
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of telmisartan 80 mg and S-amlodipine 5 mg (CKD-828)
Study: 29559771
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of individual agents (telmisartan and S-amlodipine)
Study: 30036854
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg/day
Study: 21067832
Drug: L-citrulline 5.6g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline 5.6g/day for 7 days
Study: 9878017
Drug: Drug-containing arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-containing arms of the cultures
Study: 1957129
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day for 7 days)
Study: 27515877
Drug: Basic oral
Normalized name: sodium phosphate, dibasic Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic oral care (Control)
Study: 12236852
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg alone
Study: 25801058
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg alone
Study: 9929524
Drug: Coumarin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumarin (200 mg orally, twice daily for six months)
Study: 9929524
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for six months)
Study: 2246608
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil diet (10-17 g of n-3 FAs per day)
Study: 27879460
Drug: Glucantime therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime therapy for 1 week after defervescence
Study: 16418103
Drug: New functional-sexological
Approvals — FDA: no, EMA: no, PMDA: no
Description: New functional-sexological treatment
Study: 26061132
Drug: Endoscopic thyroidectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic thyroidectomy via oral vestibular approach (ETOVA)
Study: 19487235
Drug: Bridging from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging from oral anticoagulation (OAC) to intravenous heparin infusion (n = 51)
Study: 19487235
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of oral anticoagulation (OAC) to reach an INR = 2 +/- 0.3 (n = 50)
Study: 15172900
Drug: Fondaparinux, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux, 7.5 mg (5.0 mg in patients weighing <50 kg and 10.0 mg in patients weighing >100 kg) subcutaneously once daily
Study: 9054247
Drug: Lumbar sympathetic
Normalized name: Bos taurus sympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar sympathetic nerve block with 10 ml bupivacaine (0.5%)
Study: 16534653
Drug: Intraarterial chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial chemotherapy (IARC) after potentially curative gastrectomy
Study: 10686463
Drug: ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ferrous sulfate 325 mg b.i.d.
Study: 3862158
Drug: Holistic health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic health therapy
Study: 21355147
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy
Study: 26546248
Drug: C-Reactive Protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-Reactive Protein (CRP) levels >2 mg/L
Study: 24112375
Drug: Diet+IDet (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet+IDet (Insulin detemir with dietary intervention)
Study: 24112375
Drug: IDet (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDet (Insulin detemir alone)
Study: 17243612
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and verapamil retard
Study: 14671204
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dexamethasone twice daily for 6 days
Study: 3462013
Drug: Cladosporium herbarum
Normalized name: CLADOSPORIUM HERBARUM
DrugBank: Cladosporium herbarum (DB10865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladosporium herbarum inhalation (concentrations: 1:100000, 1:10000, 1:1000, 1:100)
Study: 3462013
Drug: Histamine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine inhalation (concentrations: 0.3, 0.6, 1.2, 2.4 mg/ml)
Study: 3462014
Drug: Cladosporium herbarum
Normalized name: CLADOSPORIUM HERBARUM
DrugBank: Cladosporium herbarum (DB10865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladosporium herbarum inhalation
Study: 23866410
Drug: Once-daily tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tadalafil (10mg)
Study: 18088349
Drug: TTP889 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP889 (300 mg once daily)
Study: 12449522
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus droperidol (3 mg granisetron and 1.25 mg droperidol)
Study: 9887116
Drug: Flavored water
Normalized name: FLAVOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored water plus 6% carbohydrate and 18 mmol/l Na (CNa)
Study: 2039639
Drug: Continuous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous alfentanil infusion (100 micrograms/kg bolus followed by continuous infusion)
Study: 24535759
Drug: Cryolipolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryolipolysis treatment on the flank
Study: 23769296
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg ustekinumab
Study: 23769296
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ustekinumab
Study: 18972276
Drug: Budesonide/formoterol (320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (320/9 microg 4 times daily)
Study: 16649833
Drug: Adherence with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence with antipsychotic medication
Study: 27116024
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ciprofloxacin
Study: 20400095
Drug: Middle-dose eplerenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose eplerenone (25 mg twice daily)
Study: 6483504
Drug: DL-carnitine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-carnitine, 100 mg/kg/day for 4 days
Study: 28549895
Drug: Needle-free jet
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free jet lidocaine (J-tip) administration (0.25 mL of 2% lidocaine)
Study: 28549895
Drug: Simultaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous lidocaine injection (0.5 mL of 1% lidocaine) with corticosteroid
Study: 24104763
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of propofol 10 mg/mL, initial targeted effect-site concentration 2 μg/mL
Study: 24104763
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (PCS) of propofol, single bolus 1 mL, lockout time set at zero
Study: 1335642
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses at days 0 and 28 (group 4)
Study: 1335642
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses at days 0, 7 and 21 (group 5)
Study: 23218817
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.5% gel
Study: 26020827
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% solution
Study: 24320999
Drug: Zumba training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zumba training (twice a week for 8 weeks)
Study: 21669534
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% plain bupivacaine
Study: 21669534
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml normal saline (Control)
Study: 26976091
Drug: Escitalopram, 10
Normalized name: Escitalopram, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, 10 mg/7 days
Study: 16918728
Drug: Intragastric saline-intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric saline-intravenous motilin infusion
Study: 16918728
Drug: Intragastric acid-intravenous
Normalized name: ALCOHOL 80 mL in 100 mL INTRAGASTRIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric acid-intravenous motilin infusion
Study: 16918728
Drug: Intragastric saline-intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric saline-intravenous motilin infusion and intragastric acid-intravenous saline infusion
Study: 16918728
Drug: Control (intragastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intragastric saline-intravenous saline)
Study: 15579527
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of prednisolone (TAP) from 16 mg (range 10 to 30) to 9 mg (range 5 to 12.5) daily
Study: 15579527
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (SW) of 5 mg prednisolone
Study: 10081698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative therapy)
Study: 3517560
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BAY o1248
Study: 16206505
Drug: BCAA (branched-chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (branched-chain amino acid) granules at 12 g/day for 2 years
Study: 16206505
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy with defined daily food intake (1.0-1.4 g protein kg(‐1) day(‐1) including BCAA preparation and 25-35 kcal kg(‐1) day(‐1))
Study: 11996327
Drug: Fiduxosin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiduxosin (30 mg) under nonfasting conditions
Study: 11996327
Drug: Fiduxosin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiduxosin (30 mg) under fasting conditions
Study: 2027271
Drug: Gastric-coated calcium
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-coated calcium carbonate (3.1-3.6 g/d)
Study: 2027271
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide (2.9 g/d)
Study: 2027271
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (3.1-3.6 g/d)
Study: 17050010
Drug: Intracoronary stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary stem cell therapy
Study: 24176222
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg twice daily
Study: 24176222
Drug: IV ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ceftriaxone 2 grams daily for four weeks
Study: 21254841
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly measurement and report online (Group A)
Study: 21254841
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly measurement and report online (Group B)
Study: 11510064
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 microgram.kg‐1, i.v.) and propofol (1.5 mg.kg‐1.h‐1) during insertion of epidural catheters
Study: 21999299
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g·day(‐1))
Study: 16604827
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight hyaluronate, treated once weekly for 3 weeks
Study: 16604827
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight hyaluronate, treated once weekly for 5 weeks
Study: 1513086
Drug: Intravenous 1,25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1,25 dihydroxycholecalciferol (2 micrograms/m2)
Study: 20926897
Drug: Hospira filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Hospira filgrastim (5 μg/kg/day)
Study: 20926897
Drug: Amgen filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Amgen filgrastim (5 μg/kg/day)
Study: 17685748
Drug: Concurrent stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent stimulant treatment
Study: 9589832
Drug: Cyclofem (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclofem (medroxyprogesterone acetate, 25 mg, and estradiol cypionate, 5 mg)
Study: 6217028
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations
Study: 6387207
Drug: 2-mg nicotine
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg nicotine chewing gum
Study: 10852255
Drug: RA‐1 (ayurvedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA‐1 (ayurvedic plant extract formulation)
Study: 9663829
Drug: Claversal 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claversal 500 mg suppository b.d.
Study: 16291982
Drug: Rimonabant 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 5 mg
Study: 10099044
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine
Study: 1019862
Drug: Routine anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine anticoagulant therapy
Study: 23940729
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam
Study: 8203418
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (25 mg daily for 3 months)
Study: 8203418
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg monthly for 3 months)
Study: 3307894
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg three times daily for 6 weeks
Study: 30426694
Drug: 3-month lifestyle
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month lifestyle intervention (weekly nutrition and health classes, exercise sessions 3 days/week)
Study: 26586865
Drug: Group physical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group physical therapy (six 1-hour sessions, typically 8 participants per group)
Study: 26586865
Drug: Individual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual physical therapy (two 1-hour sessions)
Study: 7641514
Drug: Group physical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group physical therapy
Study: 26308937
Drug: Individual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual physical therapy
Study: 2024540
Drug: Prazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.5 mg)
Study: 7147145
Drug: Maternal medication
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal medication during labour
Study: 30604594
Drug: Voglibose plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose plus Metformin (vogmet)
Study: 22542748
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of aspirin (100 mg)
Study: 22542748
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of aspirin and clopidogrel (AC)
Study: 22542748
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of aspirin with clopidogrel and rabeprazole (10 mg) (ACR)
Study: 17211695
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) therapy, 3-month course, b.i.d.
Study: 10553837
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of the same solution at 5 mL/h plus PCA boluses (2.5 mL/30 min)
Study: 1864637
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) therapy (400 mg/Kg every three weeks for one year)
Study: 1864637
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline infusion equivalent volume every three weeks for one year)
Study: 29945672
Drug: Acupuncture, treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, treatment every other day, three times a week, 20 times in total.
Study: 22615015
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg plus propofol (M+P)
Study: 18004123
Drug: Amoxapine 150
Normalized name: amoxapine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxapine 150 mg/d
Study: 16045553
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (hydration and tenoxicam)
Study: 23257428
Drug: MPO (G-463A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPO (G-463A) mutant gene (GA/AA)
Study: 7914118
Drug: Proxodolol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol 10 mg tablets
Study: 3072783
Drug: BAY 1
Normalized name: Bay 125 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1 8201 (100 mg p.o.)
Study: 21192310
Drug: PPI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI therapy (pantoprazole and omeprazole)
Study: 21192310
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of mycophenolate mofetil (1.0 g twice daily)